Skip to main content

Emgality is the #1 prescribed CGRP antibody injection for preventive treatment of migraine* AND has over 90% commercial access.†,1-3

Prior authorizations are common when prescribing Emgality®. If patients' health insurance providers require prior authorizations, input patient's insurance information below to identify information you may need.

Requirements vary by plan. Information listed below includes common information that may be requested.

The search capability below is provided by an independent vendor, PrescriberPoint. Lilly USA, LLC does not control or endorse this PrescriberPoint tool. If you choose to use this tool, PrescriberPoint may collect and process your personal information as stated in their privacy policy. Lilly is not responsible for the content on this third-party site, including the privacy policy.

For more information about Lilly's privacy practices, please view the Privacy Statement and Consumer Health Privacy Notice.

*Based on total prescriptions for subcutaneous calcitonin gene-related peptide (CGRP) antibody injections written after 12/31/2021. Data as of 08/25/2023.

Source: IQVIA database as of 08/25/2023 and is subject to change without notice.

†Over 90% commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine.2 Does not take into consideration any restrictions set forth by individual plans. Data as of 09/07/2023.

  • Source: Managed Markets Insight & Technology (MMIT), LLC as of 09/07/2023 and is subject to change without notice. Please contact the plan or state for the most current information.
  • "Coverage" includes all statuses at or equivalent to Preferred, Covered, or Specialty for the preventive treatment of migraine.
  • This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.
  • Employers and employer groups may also offer additional benefit designs, which may be different than described.
  • This list may not be an exhaustive list of all plans in your area and the coverage of other plans in your area may vary.
  • The company/plan names listed do not imply their endorsement of Lilly USA, LLC or the product(s) referenced.
  • Lilly USA, LLC does not endorse any particular plan. Other product and company names mentioned herein are the trademarks of their respective owners.

CGRP=calcitonin gene-related peptide; MMIT=Managed Markets Insight & Technology; SC=subcutaneous.

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

References

  1. Data on File. Lilly USA, LLC. DOF-GZ-US-0190.
  2. Emgality. Prescribing Information. Lilly USA, LLC.
  3. Data on File. Lilly USA, LLC. DOF-GZ-US-0189.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache